Research Progress on the Application of the BCL6 Gene in Breast Cancer

Breast cancer has become one of the most common malignant tumors among women worldwide. Compared with European and American countries, the proportion of late-stage diagnoses among Chinese patients is relatively high. Although the diagnosis and treatment methods for breast cancer are constantly being updated and improved, most patients still face problems such as recurrence, metastasis, and drug resistance due to the heterogeneity of breast cancer itself. Therefore, it is urgent to find new therapeutic targets for breast cancer. B-cell lymphoma 6 protein (BCL6), as a transcriptional repressor, plays an important role in the occurrence and development of breast cancer. Studies have shown that high expression of BCL6 is closely related to the malignant characteristics, metastatic ability, and prognosis of tumors, and inhibiting its expression can enhance the sensitivity of breast cancer cells to chemotherapy drugs. This article reviews the expression and function of BCL6 in breast cancer, related molecular mechanisms, potential therapeutic targets, research progress in chemotherapy resistance, and discusses its future development and application in breast cancer.